An enzymic l-2-hydroxyglutarate biosensor based on l-2-hydroxyglutarate dehydrogenase from Azoarcus olearius.

Biosensor Fluorescent assay Resazurin l-2-Hydroxyglutarate l-2-Hydroxyglutarate dehydrogenase

Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
01 Jan 2024
Historique:
received: 19 06 2023
revised: 21 09 2023
accepted: 03 10 2023
medline: 6 11 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

l-2-Hydroxyglutarate (l-2-HG) is a critical signaling and immune metabolite but its excessive accumulation can lead to l-2-hydroxyglutaric aciduria, renal cancer, and other diseases. Development of efficient and high-throughput methods for selective l-2-HG detection is urgently required. In this study, l-2-HG dehydrogenase in Azoarcus olearius BH72 (AoL2HGDH) was screened from ten homologs and identified as an enzyme with high specificity and activity toward l-2-HG dehydrogenation. Then, an enzymatic assay-based l-2-HG-sensing fluorescent reporter, EaLHGFR which consists of AoL2HGDH and resazurin, was developed for the detection of l-2-HG. The response magnitude and limit of detection of EaLHGFR were systematically optimized using a single-factor screening strategy. The optimal biosensor EaLHGFR-2 exhibited a response magnitude of 2189.25 ± 26.89% and a limit of detection of 0.042 μM. It can accurately detect the concentration of l-2-HG in bacterial and cellular samples as well as human body fluids. Considering its desirable properties, EaLHGFR-2 may be a promising alternative for quantitation of l-2-HG in biological samples.

Identifiants

pubmed: 37862756
pii: S0956-5663(23)00682-6
doi: 10.1016/j.bios.2023.115740
pii:
doi:

Substances chimiques

alpha-hydroxyglutarate 2889-31-8
2-hydroxyglutarate dehydrogenase EC 1.1.99.2
Glutarates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115740

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shuang Hou (S)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Zhaoqi Kang (Z)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Yidong Liu (Y)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Chuanjuan Lü (C)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Xia Wang (X)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Qian Wang (Q)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Cuiqing Ma (C)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China.

Ping Xu (P)

State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, People's Republic of China.

Chao Gao (C)

State Key Laboratory of Microbial Technology, Shandong University, People's Republic of China. Electronic address: jieerbu@sdu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH